Analysts at Macquarie believe there are several significant tailwinds for ASX All Ords healthcare stock Integral Diagnostics Ltd (ASX: IDX) in the coming year, and have a bullish price target on the company’s shares.
Integral Diagnostics provides diagnostic imaging services such as magnetic resonance imaging (MRI), ultrasound, and radiography at 145 sites across Australia and New Zealand. The Macquarie team says the company stands to benefit from programs such as the National Lung Cancer Screening Program, which the federal government is tipping $264 million into.
The company will also benefit from a boost to bulk-billing, according to Macquarie:
Success in CT lung cancer screening, supported by $264m in government funding and Integral Diagnostics’ expected 20% market share, is partly offsetting a slower MRI ramp. The upcoming $7.9bn expansion of bulk billing from Nov-25 should boost GP volumes and imaging referrals, particularly in regional areas where Integral Diagnostics is strong. We forecast FY26 domestic organic revenue growth of 8%.
Several pillars to growth
The Macquarie team said synergies from the 2024 merger with Capitol Health, ongoing clinic investments and expansion of the GP bulk billing program would all be “fully realised” in the current financial year.
These factors, combined with procurement efficiencies and an expected shift of patients from public emergency departments to GP channels, position Integral Diagnostics for a step-up in margins in the second half.
The Macquarie team said the company could also increasingly shift work to radiologists working remotely, allowing for more flexibility in staffing, supporting EBITDA margin forecasts.
As the analysts said:
We see several significant tailwinds for Integral Diagnostics over FY26, with expected ongoing mix shift benefits to higher fee modalities supported by MRI deregulation, CT lung cancer screening programs. Higher annualised cost savings further supports our EBITDA margin expectations.
The Macquarie team have a 12-month price target of $3.40 on Integral Diagnostics shares, and including dividends, are forecasting a total shareholder return of 32.2% over the next year.
Integral Diagnostics declared a fully franked final dividend of 4 cents per share in August, bringing the full year payout to 6.5 cents per share.
Integral Diagnostics shares were changing hands for $2.59 on Tuesday, up 0.7%.
Macquarie said in a separate research note to clients earlier this year that it preferred Integral Diagnostics to Australian Clinical Labs Ltd (ASX: ACL), which it had a neutral rating on.
The post Macquarie predicts this ASX All Ords healthcare stock to surge past $1 billion over the next 12 months appeared first on The Motley Fool Australia.
Should you invest $1,000 in Integral Diagnostics right now?
Before you buy Integral Diagnostics shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Integral Diagnostics wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 18 November 2025
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- 2 ASX small-cap shares to buy right now
- Why I think this ASX small-cap stock is a bargain at $2.70
- Macquarie names 16 potential ASX takeover targets
Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Integral Diagnostics. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
Leave a Reply